coronary heart disease
Conditions
Interventions
control group:According to the routine PCI process, no research drugs were used before operation.
Oral group:0.5 to 1 hours before PCI, nicorandil 20mg was taken.
Venous group:Intravenous injection of nicorandil injection 6mg immediately after PCI
Sponsors
Peking University Third Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1) Aged 18~80 years old male and female; 2) patients who were diagnosed with coronary heart disease with PCI operation; 3) he or his legal representative agrees to sign the informed consent.
Exclusion criteria
Exclusion criteria: 1) coronary angiography is not suitable for PCI; 2) CABG surgery had been performed in the past; 3) acute ST segment elevation myocardial infarction over the past 7 days; 4) patients with non ST segment elevation acute coronary syndrome receiving emergency PCI treatment; 5) the target vessels were chronic complete occlusion; 6) left or right coronary opening lesions; 7) target vessel is infarct related artery, whether it is old myocardial infarction or acute myocardial infarction convalescence; 8) the immediate effect of PCI on the target vessel was not satisfactory (such as the final TIMI blood flow 1.5mm, the distal embolism or the thrombus showing the presence of contrast); 9) anaphylaxis to nicorandil, nicotinic acid or contrast agent; 10) glaucoma; 11) an erectile dysfunction therapy agent (sildenafil citrate, nicotinic acid, and TEDA) is being taken with the 5 blockage of phosphodiesterase; 12) the use of nicorandil in the past 7 days; 13) severe heart failure, cardiac function grade III or above (angina pectoris patients using NYHA classification, acute myocardial infarction patients using Killip's classification); 14) the systolic pressure was less than 90 mmHg; 15) severe bradycardia (HR < 50 / min) or II~III degree atrioventricular block; 16) atrial fibrillation or atrial flutter; 17) the history of asthma or the history of severe COPD; 18) eGFR < 30 ml/min; 19) abnormal platelet count or coagulation dysfunction; 20) the history of malignant tumor or autoimmune disease; 21) severe infection; 22) women in pregnancy or lactation.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Microcirculation resistance index; | — |
Secondary
| Measure | Time frame |
|---|---|
| CKMB;hs-TnT or cTnI; | — |
Countries
China
Contacts
Public ContactLijun Guo
Peking University Third Hospital
Outcome results
None listed